AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14618643 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeze group
Number of subjects: 390
Study 14618643 — intervention group
Group type: COMPARATOR
Intervention: Chest-Colds group
Number of subjects: 390
Study 14618643 — intervention group
Group type: COMPARATOR
Intervention: Cough Alone group
Number of subjects: 390
Study 14618643 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 390
Study 11006890 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Coronary Risk Score (derived from 10-year follow-up mortality)
Number of subjects: 0
Study 11006890 — intervention group
Group type: EXPERIMENTAL
Intervention: Global Coronary Risk Score
Number of subjects: 0
Study 8792045 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 300 mg/week
Number of subjects: 16
Study 8792045 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate 600 mg/week
Number of subjects: 16
Study 8792045 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8792045 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone administration
Number of subjects: 16
Study 1616829 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 306
Study 1616829 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 306
Study 1616829 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 306
Study 3881907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine
Number of subjects: 0
Study 3881907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 0
Study 3881907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30064297 — intervention group
Group type: EXPERIMENTAL
Intervention: Optimal Load Training (OLT)
Number of subjects: 18
Study 30064297 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Complex Training (MCT)
Number of subjects: 18
Study 30064297 — intervention group
Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 18
Study 29079411 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (1250 mg/m2 orally twice daily, days 1-14, every 21 days)
Number of subjects: 1564
Study 29079411 — intervention group
Group type: COMPARATOR
Intervention: S-1 (40 mg/m2 orally twice daily, days 1-28, every 42 days)
Number of subjects: 1564
Study 29079411 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine
Number of subjects: 1564
Study 29079411 — intervention group
Group type: COMPARATOR
Intervention: S-1
Number of subjects: 1564
Study 29079411 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine and S-1
Number of subjects: 1564
Study 26362898 — intervention group
Group type: EXPERIMENTAL
Intervention: IFNB‐1b
Number of subjects: 362
Study 26362898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 362
Study 26362898 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term follow-up
Number of subjects: 362
Study 26362898 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 362
Study 25236776 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-delivered physical activity intervention (REACH website access, pedometer)
Number of subjects: 0
Study 25236776 — intervention group
Group type: COMPARATOR
Intervention: Control group (paper diary, generic incremental step goals)
Number of subjects: 0
Study 25236776 — intervention group
Group type: EXPERIMENTAL
Intervention: Online-delivered physical activity intervention
Number of subjects: 0
Study 22341040 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive rehabilitation programme alone (group A)
Number of subjects: 44
Study 22341040 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive rehabilitation programme combined with acetaminophen 1g three times a day (group B)
Number of subjects: 44
Study 22341040 — intervention group
Group type: COMPARATOR
Intervention: Comparison of VAS score variations between groups A and B
Number of subjects: 44
Study 20356555 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose heparin (LH)
Number of subjects: 38
Study 20356555 — intervention group
Group type: COMPARATOR
Intervention: Low-dose unfractionated heparin (LUFH)
Number of subjects: 38
Study 20356555 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose low molecular weight heparin (LLMWH)
Number of subjects: 38
Study 20356555 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight unfractionated heparin (LLMWUFH)
Number of subjects: 38
Study 20356555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose heparin (HH)
Number of subjects: 38
Study 20356555 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose low molecular weight heparin (HLMWH)
Number of subjects: 38
Study 19045970 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary-negative affect subtype
Number of subjects: 131
Study 19045970 — intervention group
Group type: COMPARATOR
Intervention: Dietary subtype
Number of subjects: 131
Study 16287765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard intensity - high frequency (HardI-HiF)
Number of subjects: 492
Study 16287765 — intervention group
Group type: EXPERIMENTAL
Intervention: Hard intensity - low frequency (HardI-low-frequency)
Number of subjects: 492
Study 16287765 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity - high frequency (moderate-intensity-HiF)
Number of subjects: 492
Study 16287765 — intervention group
Group type: COMPARATOR
Intervention: Physician advice (control group)
Number of subjects: 492
Study 12114150 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-oriented group (Group 1)
Number of subjects: 57
Study 12114150 — intervention group
Group type: COMPARATOR
Intervention: Global ratings-oriented group (Group 2)
Number of subjects: 57
Study 10633209 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of iron per day (nutritional supplement made from bovine blood)
Number of subjects: 49
Study 10633209 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 49
Study 7797897 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalent live attenuated influenza A virus vaccine
Number of subjects: 50
Study 7797897 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 50
Study 2368963 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 ppm ozone (O3)
Number of subjects: 10
Study 2368963 — intervention group
Group type: COMPARATOR
Intervention: filtered air
Number of subjects: 10
Study 756057 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MPA)
Number of subjects: 5
Study 756057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study 31494443 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived substance use by friends outside of school
Number of subjects: 1285
Study 31494443 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived substance use by brothers or sisters
Number of subjects: 1285
Study 31494443 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived substance use by friends online
Number of subjects: 1285
Study 28803082 — intervention group
Group type: EXPERIMENTAL
Intervention: Outlook intervention
Number of subjects: 221
Study 28803082 — intervention group
Group type: COMPARATOR
Intervention: Relaxation meditation (RM)
Number of subjects: 221
Study 28803082 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 221
Study 26146798 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Health Utility 9D (CHU9D)
Number of subjects: 80
Study 26146798 — intervention group
Group type: EXPERIMENTAL
Intervention: d3mfs+D3MFS index score
Number of subjects: 80
Study 23141383 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% increased risk for AD
Number of subjects: 50
Study 23141383 — intervention group
Group type: COMPARATOR
Intervention: general age-related risk for AD
Number of subjects: 50
Study 21658476 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Insomnia (CBT-I)
Number of subjects: 0
Study 21658476 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Stress Reduction (MBSR)
Number of subjects: 0
Study 19705924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 5 mg
Number of subjects: 310
Study 19705924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 10 mg
Number of subjects: 310
Study 19705924 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilastine 20 mg
Number of subjects: 310
Study 16500251 — intervention group
Group type: EXPERIMENTAL
Intervention: Johns Hopkins Antibiotic Guide (JHABX) on the RIM Blackberry PDA
Number of subjects: 12
Study 16500251 — intervention group
Group type: COMPARATOR
Intervention: non‐PDA group
Number of subjects: 12
Study 15533851 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate plus hydralazine
Number of subjects: 1050
Study 11575443 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 ml water containing 10 mg Cu/L (as copper sulfate)
Number of subjects: 31
Study 11575443 — intervention group
Group type: COMPARATOR
Intervention: 200 ml distilled water
Number of subjects: 31
Study 9569658 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilingual Hong Kong students (Study 1)
Number of subjects: 894
Study 9569658 — intervention group
Group type: EXPERIMENTAL
Intervention: Undergraduates of European and Chinese ancestry living in Canada (Study 2)
Number of subjects: 894
Study 9569658 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer ratings of Chinese students (Study 3)
Number of subjects: 894
Study 9569658 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural standards for judging traits (Study 3)
Number of subjects: 894
Study 8118750 — intervention group
Group type: COMPARATOR
Intervention: Hormone Replacement Therapy (HRT) - 2 mg 17 beta-estradiol plus 1 mg norethisterone daily for 1 year
Number of subjects: 66
Study 8118750 — intervention group
Group type: COMPARATOR
Intervention: Nandrolone Decanoate (ND) - 50 mg i.m. every 3 weeks for 1 year
Number of subjects: 66
Study 8118750 — intervention group
Group type: COMPARATOR
Intervention: Placebo for HRT
Number of subjects: 66
Study 8118750 — intervention group
Group type: COMPARATOR
Intervention: Placebo for ND
Number of subjects: 66
Study 3415895 — intervention group
Group type: EXPERIMENTAL
Intervention: MHS(B) - morphine hydrogel suppository with high initial release rate
Number of subjects: 0
Study 3415895 — intervention group
Group type: EXPERIMENTAL
Intervention: MHS(S) - morphine hydrogel suppository with constant release rate
Number of subjects: 0
Study 31209260 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitrectomy with ILM peeling
Number of subjects: 62
Study 29231336 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture based on the theory of 'the compatibility of the five meridians' in Huxiang
Number of subjects: 60
Study 29231336 — intervention group
Group type: COMPARATOR
Intervention: Conventional triple drugs (omeprazole, amoxicillin and clarithromycin) for Hp positive patients, and omeprazole for Hp negative patients
Number of subjects: 60
Study 29231336 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 60
Study 25872149 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose treatment of AM-101
Number of subjects: 0
Study 25872149 — intervention group
Group type: EXPERIMENTAL
Intervention: Three doses of AM-101 over 2 weeks
Number of subjects: 0
Study 25872149 — intervention group
Group type: EXPERIMENTAL
Intervention: Three injections of AM-101 over 3 consecutive days
Number of subjects: 0
Study 23715452 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum retraction by Roeko stay put non impregna cords
Number of subjects: 53
Study 23715452 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulders prepared at the gingival margin
Number of subjects: 53
Study 23715452 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder located subgingivally
Number of subjects: 53
Study 23715452 — intervention group
Group type: COMPARATOR
Intervention: Control group (40 teeth)
Number of subjects: 53
Study 22019971 — intervention group
Group type: EXPERIMENTAL
Intervention: VR treadmill training
Number of subjects: 14
Study 22019971 — intervention group
Group type: COMPARATOR
Intervention: Traditional treadmill training
Number of subjects: 14
Study 22019971 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 14
Study 18587524 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive syndrome (defined as depressed mood and three additional depressive symptoms)
Number of subjects: 838
Study 18587524 — intervention group
Group type: COMPARATOR
Intervention: Control condition (without depressive symptoms)
Number of subjects: 838
Study 16494543 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-trocar laparoscopic-assisted appendectomy
Number of subjects: 83
Study 16494543 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparoscopic appendectomy
Number of subjects: 83
Study 16494543 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversion of initial procedure (due to excessive body weight)
Number of subjects: 83
Study 12956495 — intervention group
Group type: EXPERIMENTAL
Intervention: IMZ two-stage implants
Number of subjects: 40
Study 12956495 — intervention group
Group type: COMPARATOR
Intervention: ITI one-stage implants
Number of subjects: 40
Study 10939551 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin
Number of subjects: 256
Study 10939551 — intervention group
Group type: COMPARATOR
Intervention: Fosphenytoin
Number of subjects: 256
Study 9553237 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 150 micrograms
Number of subjects: 112
Study 9553237 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 60 mg
Number of subjects: 112
Study 9553237 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline (Placebo)
Number of subjects: 112
Study 8368558 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.5%-1%)
Number of subjects: 80
Study 8368558 — intervention group
Group type: EXPERIMENTAL
Intervention: Enflurane (1.5%-2%)
Number of subjects: 80
Study 8368558 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane (1.2%-1.8%)
Number of subjects: 80
Study 8368558 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Intravenous Anesthesia (6.0 mg.kg‐1 x h‐1 propofol)
Number of subjects: 80
Study 8368558 — intervention group
Group type: COMPARATOR
Intervention: Comparison between halothane and TIVA
Number of subjects: 80
Study 8368558 — intervention group
Group type: COMPARATOR
Intervention: Comparison between enflurane and TIVA
Number of subjects: 80
Study 2947345 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (Provera) 20 mg orally thrice daily for one month
Number of subjects: 11
Study 2947345 — intervention group
Group type: COMPARATOR
Intervention: Placebo for one month
Number of subjects: 11
Study 2947345 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate
Number of subjects: 11
Study 30257641 — intervention group
Group type: EXPERIMENTAL
Intervention: As concentration >=0.02 mg/kg
Number of subjects: 833
Study 30257641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ni concentration >=0.1232 mg/kg
Number of subjects: 833
Study 30257641 — intervention group
Group type: EXPERIMENTAL
Intervention: Se concentration >=0.02 mg/kg
Number of subjects: 833
Study 30257641 — intervention group
Group type: EXPERIMENTAL
Intervention: Fe concentration >=6.9153 mmol/L
Number of subjects: 833
Study 30257641 — intervention group
Group type: EXPERIMENTAL
Intervention: Ni concentration >=0.0965 mg/kg
Number of subjects: 833
Study 28870472 — intervention group
Group type: EXPERIMENTAL
Intervention: High β‐glucan barley (4.4 g/d)
Number of subjects: 100
Study 28870472 — intervention group
Group type: COMPARATOR
Intervention: β‐glucan‐free barley (placebo)
Number of subjects: 100
Study 28870472 — intervention group
Group type: EXPERIMENTAL
Intervention: High β‐glucan barley (4.4 g/d) in subgroup with VFA ≥100 cm2
Number of subjects: 100
Study 28870472 — intervention group
Group type: COMPARATOR
Intervention: β‐glucan‐free barley (placebo) in subgroup with VFA ≥100 cm2
Number of subjects: 100
Study 26125415 — intervention group
Group type: EXPERIMENTAL
Intervention: mobile health+CarePartner (mHealth+CP)
Number of subjects: 369
Study 24908523 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular suture with No '1' polyfilament (petcryl)
Number of subjects: 138
Study 24908523 — intervention group
Group type: COMPARATOR
Intervention: Intermittent suture with nylon 2‐0
Number of subjects: 138
Study 24908523 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Subcuticular and Intermittent)
Number of subjects: 138
Study 24908523 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged rupture of membrane >18 hours
Number of subjects: 138
Study 20350051 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycyrrhizin salt tablet 150 mg twice daily for 14 consecutive days
Number of subjects: 18
Study 20350051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 18486720 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and medication therapy to lower urine supersaturation
Number of subjects: 0
Study 16904419 — intervention group
Group type: EXPERIMENTAL
Intervention: St. John's wort (SJW) with Loestrin 1/20
Number of subjects: 15
Study 16904419 — intervention group
Group type: COMPARATOR
Intervention: Loestrin 1/20
Number of subjects: 15
Study 12462959 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management program
Number of subjects: 63
Study 12462959 — intervention group
Group type: EXPERIMENTAL
Intervention: Hierarchical regression model
Number of subjects: 63
Study 10509788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYCLO) at a dose of 1200 mg/m2
Number of subjects: 61
Study 10509788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS) at a dose of 5 g/m2
Number of subjects: 61
Study 10509788 — intervention group
Group type: COMPARATOR
Intervention: Both CYCLO and IFOS
Number of subjects: 61
Study 10509788 — intervention group
Group type: EXPERIMENTAL
Intervention: Ifosfamide (IFOS)
Number of subjects: 61
Study 10509788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYCLO)
Number of subjects: 61
Study 10509788 — intervention group
Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 61
Study 8948244 — intervention group
Group type: EXPERIMENTAL
Intervention: Hansson hook‐pins
Number of subjects: 47
Study 8948244 — intervention group
Group type: COMPARATOR
Intervention: Charnley hip replacement
Number of subjects: 47
Study 1781536 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 ml of clear fluid 1.5‐2 hours before anaesthesia
Number of subjects: 100
Study 1781536 — intervention group
Group type: COMPARATOR
Intervention: Fasted from midnight the night before
Number of subjects: 100
Study 6792382 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein-containing solution with hypertonic glucose
Number of subjects: 0
Study 6792382 — intervention group
Group type: COMPARATOR
Intervention: Protein-free solution
Number of subjects: 0
Study 30831601 — intervention group
Group type: EXPERIMENTAL
Intervention: Current use of soy supplements
Number of subjects: 76442
Study 29170461 — intervention group
Group type: EXPERIMENTAL
Intervention: Described‐High group
Number of subjects: 0
Study 29170461 — intervention group
Group type: COMPARATOR
Intervention: Described‐Low group
Number of subjects: 0
Study 29170461 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupil dilation and behavioral data
Number of subjects: 0
Study 29170461 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin conductance responses and pupil dilation
Number of subjects: 0
Study 27256356 — intervention group
Group type: EXPERIMENTAL
Intervention: nasally administered oxytocin
Number of subjects: 61
Study 27256356 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 61
Study 24393351 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal collagen cross-linking (CXL)
Number of subjects: 100
Study 24393351 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 100
Study 21928106 — intervention group
Group type: EXPERIMENTAL
Intervention: VC-APS arm (vinorelbine and cisplatin combined with Astragalus polysaccharide)
Number of subjects: 136
Study 21928106 — intervention group
Group type: COMPARATOR
Intervention: VC arm (vinorelbine and cisplatin)
Number of subjects: 136
Study 21928106 — intervention group
Group type: EXPERIMENTAL
Intervention: VC-APS arm
Number of subjects: 136
Study 21928106 — intervention group
Group type: COMPARATOR
Intervention: VC arm
Number of subjects: 136
Study 19501409 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gatifloxacin for 3 days before injection
Number of subjects: 129
Study 19501409 — intervention group
Group type: COMPARATOR
Intervention: Povidone-iodine (PVI) alone
Number of subjects: 129
Study 19501409 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical gatifloxacin in combination with PVI
Number of subjects: 129
Study 17186421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone-delivered and mailed intervention for smoking cessation
Number of subjects: 582
Study 17186421 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored telephone-delivered and mailed intervention for increased fruit and vegetable consumption
Number of subjects: 582
Study 17186421 — intervention group
Group type: COMPARATOR
Intervention: Control group for smoking cessation
Number of subjects: 582
Study 17186421 — intervention group
Group type: COMPARATOR
Intervention: Control group for fruit and vegetable consumption
Number of subjects: 582
Study 10857960 — intervention group
Group type: EXPERIMENTAL
Intervention: KJM fiber-enriched test biscuits (0.5 g of glucomannan per 100 kcal of dietary intake or 8-13 g/day)
Number of subjects: 11
Study 10857960 — intervention group
Group type: COMPARATOR
Intervention: Wheat bran fiber (WB) control biscuits
Number of subjects: 11
Study 9170466 — intervention group
Group type: EXPERIMENTAL
Intervention: Domiciliary antenatal fetal monitoring
Number of subjects: 150
Study 9170466 — intervention group
Group type: COMPARATOR
Intervention: In-hospital monitoring
Number of subjects: 150
Study 1441495 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation program
Number of subjects: 6347
Study 1441495 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 6347
Study 4022732 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 20‐min. sessions of training in test‐taking skills particular to the Stanford Achievement Test
Number of subjects: 16
Study 4022732 — intervention group
Group type: COMPARATOR
Intervention: Control group (not trained)
Number of subjects: 16